$Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report$

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

<h3>Abstract</h3><p dir="ltr">Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the...

Full description

Saved in:

Bibliographic Details
Main Author:	Meshaal Alanzi (21406994) (author)
Other Authors:	Mohammad Abu-Tineh (14829313) (author), Lajos Szabados (16561323) (author), MZ Sharaf Eldean (21406997) (author), Sali Alatasi (14777713) (author), Ruba Y Taha (14779351) (author), Sarah A Elkourashy (21407000) (author)
Published:	2023
Subjects:	Biomedical and clinical sciences Cardiovascular medicine and haematology Oncology and carcinogenesis Burkitt’s lymphoma polatuzumab Lymphoma anti CD79b resistant lymphoma
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Similar Items